NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
Lumos Pharma
Abramson Cancer Center at Penn Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aravive, Inc.
Ohio State University Comprehensive Cancer Center
University Hospital Tuebingen
Silence Therapeutics GmbH
Dana-Farber Cancer Institute